Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (81-90 of 265) with videos related to

Pageof 27
Sort By:
Therapeutic Advances in Medical Oncology|July 29, 2024
Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global networkAlessandra Fabi, Elizabeth M Gavioli, Renuka Wakade, et al.
Journal of Personalized Medicine|April 27, 2024
Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research HospitalInbal Dona Amar, Gianluca Franceschini, Camilla Nero, et al.
Anticancer Research|August 9, 2015
The Role of PET [18F]FDOPA in Evaluating Low-grade GliomaVeronica Villani, Carmine M Carapella, Agostino Chiaravalloti, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2010
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclinesPatrizia Vici, Alessandra Fabi, Giulio Metro, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.
BMC Cancer|October 23, 2012
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapyAlessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, et al.
Cancers|February 25, 2022
Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 YearsRosa Falcone, Pasquale Lombardi, Marco Filetti, et al.
Breast (Edinburgh, Scotland)|May 3, 2008
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Giulio Metro, Gianluigi Ferretti, et al.
Frontiers in Oncology|December 9, 2022
Paget's disease of the breast: Our 20 years' experienceLorenzo Scardina, Alba Di Leone, Stefano Magno, et al.
Anticancer Research|July 28, 2004
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II studyAlessandra Fabi, Paola Papaldo, Maria Simona Pino, et al.
Pageof 27

Showing results (81-90 of 265) with videos related to

Sort By:
Pageof 27
Therapeutic Advances in Medical Oncology|July 29, 2024
Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global networkAlessandra Fabi, Elizabeth M Gavioli, Renuka Wakade, et al.
Journal of Personalized Medicine|April 27, 2024
Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research HospitalInbal Dona Amar, Gianluca Franceschini, Camilla Nero, et al.
Anticancer Research|August 9, 2015
The Role of PET [18F]FDOPA in Evaluating Low-grade GliomaVeronica Villani, Carmine M Carapella, Agostino Chiaravalloti, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2010
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclinesPatrizia Vici, Alessandra Fabi, Giulio Metro, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.
BMC Cancer|October 23, 2012
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapyAlessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, et al.
Cancers|February 25, 2022
Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 YearsRosa Falcone, Pasquale Lombardi, Marco Filetti, et al.
Breast (Edinburgh, Scotland)|May 3, 2008
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Giulio Metro, Gianluigi Ferretti, et al.
Frontiers in Oncology|December 9, 2022
Paget's disease of the breast: Our 20 years' experienceLorenzo Scardina, Alba Di Leone, Stefano Magno, et al.
Anticancer Research|July 28, 2004
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II studyAlessandra Fabi, Paola Papaldo, Maria Simona Pino, et al.
Pageof 27